Investment
Features
FeesSafety
Academy
More
Pluang+

Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs Summit Therapeutics Inc (SMMT) Price & Performance

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETFTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs Summit Therapeutics Inc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77, while Summit Therapeutics Inc trades at $15.25 (market cap $12.06B). The key difference: State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

FLRNSMMT
Sector
Sector/ThematicHealth
52-Week High
$30.86$26.98
52-Week Low
$30.65$12.55
Market Cap
$12.06B
Enterprise Value
$11.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN trades at $30.77, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though the RSI suggests potential oversold conditions. The company has maintained consistent dividend payments of $0.11 per share through mid-2026. Current financial ratios including P/E, P/S, and ROE are unavailable in the provided data, limiting fundamental assessment.

The outlook remains cautious due to bearish technical signals and limited fundamental visibility. Investment opportunity exists in the steady dividend yield, but risks include potential interest rate sensitivity as highlighted in recent financial commentary. Investors should seek updated financial statements for comprehensive analysis given the missing valuation metrics.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.

Returns comparison

Trailing returns across standard periods

About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF

FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.

Read more on FLRN

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT